Evolving the Treatment of Renal Cell Carcinoma: Highlights from KCRS and ASCO 2023

Centering discussion on the KCRS 2023 annual meeting, experts in renal cell carcinoma elucidate data from the CLEAR and TRAVERSE studies in clear cell disease.

Expert panelists consider how updated data from the CLEAR trial of lenvatinib + pembrolizumab in advanced clear cell RCC have impacted their real-world clinical practice.

In the context of the available frontline treatment armamentarium for advanced clear cell RCC, key opinion leaders consider how they would select or sequence therapy.

Panelists shed light on key factors that help to inform the selection of frontline therapy in patients with advanced clear cell renal cell carcinoma.

Switching its focus to non-clear cell RCC, the panel reviews data presented at ASCO 2023 on KEYNOTE-B61, combining lenvatinib + pembrolizumab in this setting.

Key opinion leaders in the field of renal cell carcinoma management reflect on recent data with IO/TKI combination therapy in patients with non-clear cell disease.

A brief discussion centered on optimal treatment strategies for patients with chromophobe or papillary kidney cancers.

Centering discussion on sarcomatoid and rhabdoid non-clear cell renal cell carcinoma, panelists consider frontline IO-based regimens and their value in this setting.

Closing out their program on renal cell carcinoma management, key opinion leaders share closing thoughts on emerging therapies and how the field is evolving.

Brian I. Rini, MD, led a panel where he and his colleagues discussed the results of the CLEAR trial and its implications in renal cell carcinoma.